To access this material please log in or register

Register Authorize

Additional criteria for stratifying the ischemic stroke risk in patients with atrial fibrillation and one non‑sex‑related point on the CHA2DS2‑VASc scale

Nicolin D. Y.1, Grachev V. G.2, Lipchenko A. A.2, Fokina E. G.1, Arkhipov M. V.2
1 – Limited Liability Company Medical Foundation “Novaya Bolnitsa”, Zavodskaya str. 29, Ekaterinburg 620109
2 – Federal State Budgetary Educational Institution of Higher Professional Education “Ural State Medical University” of the Ministry of Health of the Russian Federation, Repina str. 3, Ekaterinburg 620028

Keywords: atrial fibrillation, stroke, risk stratification

DOI: 10.18087/rhj.2017.3.2353

Background. The oral anticoagulant treatment is recommended for prevention of stroke and other thromboembolic complications related with atrial fibrillation (AF). Is was suggested to use formal scales, specifically the CHA2DS2‑VASc scale, to determine indications for this treatment. Aim. To identify characteristics not included into the CHA2DS2‑VASc scale, which influence the risk of ischemic stroke in patients with AF and one non‑sex‑related risk factor (RF) for thromboembolic complications on this scale. Materials and methods. A “case‑control” study was performed using data of a retrospective analysis of case reports of patients with AF. The main group consisted of patients with non‑valvular AF and one additional to sex CHA2DS2‑VASc RF who were admitted during the period preceding the development of stroke. The reference group included matched by demographic characteristics patients with non‑valvular AF and one additional to sex CHA2DS2‑VASc RF who had no stroke or systemic embolism. Medical history data, results of ECG, EchoCG and ultrasound duplex scanning of brachiocephalic arteries (USDS BCA) were analyzed. Results. The main group included 50 patients aged 62.5 (58.75; 69.25), of which women were 32%; the reference group included 68 patients aged 62 (57.0; 64.0), of which 38.2% were women. The main group compared to the reference group had significantly higher incidences of permanent AF (48% vs 23.9%; р=0.01), EchoCG signs of LV hypertrophy (LVH) (68% vs 44.1%; р=0.015), and thickened intima‑media complex (IMC) >0.9 mm as shown by USDS BCA (68% vs 22.1%; р<0.0001). The monofactorial analysis demonstrated a significant increase in risk for ischemic stroke in the presence of permanent AF (HR , 2.552; 95% CI from 1.233 to 5.281), EchoCG evidence of LVH (HR , 2.673; 95% CI from 1.252 to 5.709), and thickened IMC (HR , 5.536; 95% CI from 2.643 to 11.594). Conclusion. Data of EchoCG and USDS BCA and the AF type should be taken into account in evaluating the risk for ischemic stroke and considering administration of oral anticoagulants for patients with AF and one additional to sex CHA2DS2‑VASc RF who have non‑absolute indications for anticoagulant therapy.
  1. Miyasaka Y. Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future Prevalence. Circulation. 2006;114(2):119–25. DOI:10.1161/CIRCULATIONAHA.105.595140.
  2. Сулимов В. А., Голицын С. П., Панченко Е. П., Попов С. В., Ревишвили А. Ш., Шубик Ю. В. и др. Диагностика и лечение фибрилляций предсердий. Рекомендации РКО, ВНОА И АССХ. Российский кардиологический журнал. 2013;4 S3:1–100 [Sulimov V. A., Goliczy`n S. P., Panchenko E. P., Popov S. V., Revishvili A. Sh., Shubik Yu. V. i dr. Diagnostika i lechenie fibrillyaczij predserdij. Rekomendaczii RKO, VNOA I ASSX. Rossijskij kardiologicheskij zhurnal. 2013;4 S3:1–100].
  3. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–962. DOI:10.1093/eurheartj/ehw210.
  4. Бритов А. Н., Поздняков Ю. М., Волкова Э. Г., Драпкина О. М., Еганян Р. А., Кисляк О. М. и др. Национальные рекомендации по кардиоваскулярной профилактике. Кардиоваскулярная терапия и профилактика. 2011;10(6 S2):1–64 [Britov A. N., Pozdnyakov Yu. M., Volkova E`. G., Drapkina O. M., Eganyan R . A., Kislyak O. M. i dr. Naczional`ny`e rekomendaczii po kardiovaskulyarnoj profilaktike. Kardiovaskulyarnaya terapiya i profilaktika. 2011;10(6 S2):1–64].
  5. Lang R, Bierig M, Devereux R, Flachskampf F, Foster E, Pellikka P et al. Recommendations for chamber quantification. European Journal of Echocardiography. 2006;7(2):79–108. DOI:10.1016/j.euje.2005.12.014.
  6. Savino JA, Halperin JL. Should Patients With Atrial Fibrillation and 1 Stroke Risk Factor (CHA2DS2‑VASc Score 1 in Men, 2 in Women) Be Anticoagulated? The CHA2DS2‑VASc 1 Conundrum: Decision Making at the Lower End of the Risk Spectrum. Circulation. 2016;133(15):1504–1511; discussion 1511. DOI:10.1161/CIRCULATIONAHA.115.016715.
  7. Olesen JB, Fauchier L, Lane DA, Taillandier S, Lip GYH. Risk Factors for Stroke and Thromboembolism in Relation to Age Among Patients With Atrial Fibrillation. Chest. 2012;141(1):147–53. DOI:10.1378/chest.11‑0862.
  8. Lip GYH, Skjøth F, Rasmussen LH, Larsen TB. Oral Anticoagulation, Aspirin, or No Therapy in Patients With Nonvalvular AF With 0 or 1 Stroke Risk Factor Based on the CHA2DS2‑VASc Score. Journal of the American College of Cardiology. 2015;65(14):1385–94. DOI:10.1016/j.jacc.2015.01.044.
  9. Ganesan AN, Chew DP, Hartshorne T, Selvanayagam JB, Aylward PE, Sanders P et al. The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta‑analysis. European Heart Journal. 2016;37(20):1591–602. DOI:10.1093/eurheartj/ehw007.
  10. Apostolakis S, Sullivan RM, Olshansky B, Lip GYH. Left ventricular geometry and outcomes in patients with atrial fibrillation: The AFFIRM Trial. International Journal of Cardiology. 2014;170(3):303–8. DOI:10.1016/j.ijcard.2013.11.002.
  11. Boyd AC, McKay T, Nasibi S, Richards DAB, Thomas L. Left ventricular mass predicts left atrial appendage thrombus in persistent atrial fibrillation. European Heart Journal ‑ Cardiovascular Imaging. 2013;14(3):269–75. DOI:10.1093/ehjci/jes153.
  12. Verdecchia P, Reboldi G, Di Pasquale G, Mazzotta G, Ambrosio G, Yang S et al. Prognostic Usefulness of Left Ventricular Hypertrophy by Electrocardiography in Patients With Atrial Fibrillation (from the Randomized Evaluation of Long‑Term Anticoagulant Therapy Study). The American Journal of Cardiology. 2014;113(4):669–75. DOI:10.1016/j.amjcard.2013.10.045.
  13. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of Clinical Cardiovascular Events With Carotid Intima‑Media Thickness: A Systematic Review and Meta‑Analysis. Circulation. 2007;115(4):459–67. DOI:10.1161/CIRCULATIONAHA.106.628875.
  14. Bekwelem W, Jensen PN, Norby FL, Soliman EZ, Agarwal SK, Lip GYH et al. Carotid Atherosclerosis and Stroke in Atrial Fibrillation: The Atherosclerosis Risk in Communities Study. Stroke. 2016;47(6):1643–6. DOI:10.1161/STROKEAHA.116.013133.
Nicolin D. Y., Grachev V. G., Lipchenko A. A., Fokina E. G., Arkhipov M. V. Additional criteria for stratifying the ischemic stroke risk in patients with atrial fibrillation and one non‑sex‑related point on the CHA2DS2‑VASc scale. Russian Heart Journal. 2017;16 (3):197–203

To access this material please log in or register

Register Authorize
Ru En